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Objective: Chemotherapy‐induced sensory peripheral neuropathy (CIPN) is com-
mon among colorectal cancer (CRC) survivors. The aim of this study was to examine
whether CIPN is associated with both psychological distress (ie, anxiety and depres-
sion) and fatigue and whether the relationship between CIPN and fatigue can (partly)
be explained by psychological distress.
Methods: All CRC survivors diagnosed between 2000 and 2009 as registered by
the population‐based Netherlands Cancer Registry (Eindhoven region) were eligible
for participation. Chemotherapy‐treated survivors completed questions on CIPN
(EORTC QLQ‐CIPN20), psychological distress (HADS), and fatigue (FAS) on average
5.6 years after diagnosis. Simple and multiple mediation analyses were performed
to examine anxiety and depression as possible mediators in the association between
CIPN and fatigue.
Results: Survivors with high (ie, upper 30% of scores) CIPN (n = 172) reported more
anxiety and depressive symptoms and more fatigue compared with those with low
CIPN (n = 299). Furthermore, among survivors with high CIPN, those who were anx-
ious, depressed, or both reported more fatigue compared with those without psycho-
logical distress. These differences were clinically relevant. Finally, mediation analyses
showed that while CIPN was directly associated with fatigue, the relationship
between CIPN and fatigue was also significantly mediated by both anxiety and
depression.
Conclusions: CRC survivors with high CIPN report more fatigue, especially those
who are also anxious and/or depressed. More research is needed on the direction
of the relationship between CIPN, psychological distress, and fatigue. For now, the
treatment of fatigue should also focus on addressing psychological distress, as
treating fatigue alone might not be sufficient.- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided
by John Wiley & Sons Ltd
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oncology, PROFILES1 | BACKGROUND
Colorectal cancer (CRC) is the third most common cancer among men
andwomen, and the prevalence is still increasing.1 Due to the increasing
prevalence, more patients are living with the side effects of this condi-
tion and its treatment. Chemotherapy‐induced peripheral neuropathy
(CIPN), a side effect of chemotherapy, is common among CRC patients2
and has been found to severely impact HRQoL.3 Symptoms of CIPN are
predominantly sensory and present as tingling, numbness, and aching or
burning pain in the fingers, hands, toes, and feet.4 While CIPN symp-
toms reverse or improve in the majority of patients after chemotherapy
treatment, a significant proportion of patients experience chronic
CIPN.2 Moreover, symptoms can develop years after treatment has
ended.5 Due to the high prevalence of CRC in combination with the lack
of a well‐accepted treatment or prevention strategy against CIPN,6
more CRC survivors could be affected by CIPN.
Besides CIPN, fatigue is also a highly prevalent problem among can-
cer survivors, with prevalence rates up to 90%.7 Fatigue is one of the
most debilitating symptom among cancer patients and has been related
to a worse HRQoL,8,9 a higher cancer recurrence,10 and a poorer sur-
vival.10 CIPN has been related to fatigue in previous research,3,5,11 but
the mechanisms underlying this relationship are not well understood.
Psychological distress, that is depression and anxiety, has been
found to be strongly correlated with fatigue.7,12,13 Also, while the stud-
ies on the relationship between CIPN and psychological distress are
rather scarce, the majority did find that those with CIPN symptoms
report more depression and anxiety.14-17 Therefore, it is reasonable to
argue that psychological distress could be a possible mechanism under-
lying the relationship between CIPN and fatigue. However, to our
knowledge, this has not been examined before.
As interventions are not always successful in treating fatigue
among individuals with cancer18 and since there is no prevention or
treatment available for CIPN, knowledge on the mechanisms underly-
ing the relationship between CIPN and fatigue is crucial for developing
efficacious interventions for fatigue. Therefore, in this secondary anal-
ysis, we examined whether CIPN is associated with both psychological
distress and fatigue and whether the relationship between CIPN and
fatigue can (partly) be explained by psychological distress. We hypoth-
esize that CIPN will be associated with more anxiety, depression, and
fatigue and that the relationship between CIPN and fatigue will be
mediated by both anxiety and depression.
2 | METHODS
2.1 | Settings and participants
Details of the data collection have previously been described.3
However, as the Netherlands Cancer Registry (NCR) is updatedcontinuously, additional details of clinical characteristics were avail-
able for analysis in this study. In brief, this prospective, population‐
based survey was set up in December 2010 by using data from the
NCR, which compiles data of all individuals newly diagnosed with
cancer.19 Everyone diagnosed with CRC between 2000 and 2009 as
registered in the Eindhoven region of the NCR was eligible for partic-
ipation. Those with unverifiable addresses, with cognitive impairment,
who died prior to the start of the study or were terminally ill, and
those with carcinoma in situ or already included in another study were
excluded. One year later, the second data wave took place, which
included a questionnaire on CIPN. Therefore, the data presented in
this cross‐sectional study are based on the second data wave. At this
time, patients were diagnosed between 2 and 12 years ago. This study
was approved by the Central Committee on Research Involving
Human Subjects (approval number NL23463.015.08) and the Medical
Ethics Committee of the Maxima Medical Centre (approval number
0822). All survivors signed informed consent.2.2 | Data collection
Data collectionwas performedwithin PROFILES (www.profilesregistry.
nl), which is a registry for the study of the physical and psychosocial
impact of cancer and its treatment. PROFILES contains a large web‐
based component and is linked directly to clinical data from the NCR.
Details of the PROFILES data collection have previously been
described.20 CRC survivors were informed of the study via a letter from
their specialist if they still had follow‐up care visits in the hospital; those
who did no longer have any follow‐up care received the letter from
their former specialist. Nonrespondents were sent a reminder letter
and paper‐and‐pencil questionnaire within 2 months.2.3 | Study measures
2.3.1 | Sociodemographic and clinical characteristics
Survivor's sociodemographic (ie, age, sex) and clinical information were
available from the NCR. Comorbidity at time of the study was assessed
with the adapted Self‐Administered Comorbidity Questionnaire
(SCQ).21 Depression was excluded as a comorbidity since depression
is one of the possible mediators in this study. Questions on marital sta-
tus and educational level were added to the questionnaire.2.3.2 | Chemotherapy‐induced peripheral
neuropathy
As a previous study among the same sample of CRC survivors3 only
found a difference in sensory peripheral neuropathy symptoms
1928 BONHOF ET AL.between those who received chemotherapy and those who did not,
we will only focus on the sensory symptoms of CIPN in this study.
Chemotherapy‐induced sensory peripheral neuropathy was assessed
with the EORTC QLQ Chemotherapy‐Induced Peripheral Neuropa-
thy20 (EORTC QLQ‐CIPN20).22 Respondents are asked how often
they had experienced the specific sensory neuropathy symptom in
the past week. Items are answered on a Likert scale ranging from (1)
not at all to (4) very much. Scores were linearly transformed to a 0 to
100 scale, with higher scores indicating more complaints.TABLE 1 Sociodemographic and clinical characteristics of the chemother
induced sensory peripheral neuropathy
CRC Survivors with
low CIPN (n = 299, 7
Age at time of survey (mean (SD)) 66.4 (9.9)
Sex (female) 120 (40%)




















Well differentiated 26 (9%)
Moderately differentiated 185 (62%)
Poorly differentiated 40 (13%)
Unknown 48 (16%)
Comorbidities associated with PN‐like symptomsb
Diabetes mellitus 41 (15%)
Rheumatoid arthritis 15 (5%)
Osteoarthritis 51 (18%)
Abbreviations: SD, standard deviation; CIPN, chemotherapy‐induced periphera
aEducation: low (no or primary school), medium (lower general secondary educ
training, university).
bMost frequent comorbidities associated with peripheral neuropathy.2.3.3 | Psychological distress
The Hospital Anxiety and Depression Scale (HADS) was used to assess
anxiety (HADS‐A) and depressive symptoms (HADS‐D).23 It consists
of 14 items, answered on a 4‐point Likert scale. Total scores range
from 0 to 21, with higher scores indicating more anxiety or depression.
A cutoff value of 8 for each subscale was used to identify a clinically
relevant level of anxiety or depression.24 The HADS is a valid and reli-



































ation or vocational training), high (preuniversity education, high vocational
FIGURE 1 Mean fatigue (FAS) scores of colorectal cancer survivors
with high chemotherapy‐induced sensory peripheral neuropathy
(CIPN), stratified by anxiety and depression, or both. 1 High CIPN
versus high CIPN + anxious. 2 High CIPN versus high CIPN +
depressed. 3 High CIPN versus high CIPN + anxious and depressed. ^
Clinically relevant difference28
BONHOF ET AL. 19290.82 (HADS‐D), and a sensitivity and specificity score of ≈0.80 for
both subscales.25 In the current study, Cronbach alpha was 0.82 for
both subscales.
2.3.4 | Fatigue
Fatigue was assessed with the Fatigue Assessment Scale (FAS),26
which consists of 10 items answered on a Likert scale ranging from
(1) never to (5) always. Total scores range from 10 to 50, with higher
scores reflecting more fatigue. The FAS has good psychometric quali-
ties.26 In this study, Cronbach alpha was 0.85.
2.4 | Statistical analyses
NCR data on sociodemographic and clinical characteristics enabled us
to compare respondents, nonrespondents, and those with unverifiable
addresses, using t tests for continuous variables and chi‐squared tests
for categorical variables. The same analyses were done to compare
differences in sample characteristics between chemotherapy‐treated
survivors with high CIPN (ie, upper 30% of scores) and those with
low CIPN (ie, the other 70% of scores). Specifically, those who were
categorized into high CIPN scored greater than 11.11 on the sensory
scale of the CIPN20.
Anxiety, depression, and fatigue were compared between survi-
vors with high versus low CIPN using t tests for continuous outcomes
and chi‐squared tests for differences in clinically relevant level of anx-
iety (HADS‐A ≥8) and depression (HADS‐D ≥8). In addition, among
those with high CIPN, mean fatigue scores were compared between
(1) survivors with high CIPN, (2) survivors with high CIPN, who are
anxious, (3) survivors with high CIPN, who are depressed, and (4) sur-
vivors with high CIPN, who are both anxious and depressed. To deter-
mine whether differences could be considered clinically relevant, the
minimal important differences (MIDs) for the HADS (anxiety ≥1.3,
depression ≥1.4)27 and FAS (≥4.0) scores were used that were found
in previous research.28 A MID is defined as the smallest difference in
score of interest that patients perceive as important.29 To evaluate
the mediating role of anxiety and depression in the relationship
between CIPN and fatigue, PROCESS was used.30 PROCESS esti-
mates the indirect effect and bias‐corrected confidence intervals
(CIs) using bootstrapping. An indirect effect, which together with its
CI indicates whether a variable mediates the relationship between var-
iables X and Y, is considered significant when the CI does not include
zero. In this study, model 4 within PROCESS was used, and all analy-
ses were based on 5000 bootstrapping samples. Two simple mediation
analyses were performed: one with anxiety as a possible mediator and
one with depression as a possible mediator. A multiple mediation anal-
ysis, in which both anxiety and depression were added, was then con-
ducted to examine whether anxiety and depression would remain
significant mediators in the relationship between CIPN and fatigue,
while statistically controlling for each other. In all mediation analyses,
sex, age, stage, time since diagnosis, number of comorbidities, partner
status, educational level, and tumor type (rectal vs colon) were
included as covariables.All tests were two‐sided and considered to be significant if P <
0.05. All statistical analyses were performed using SPSS 22 (IBM SPSS
Statistics for Windows, Version 22.0 Armonk, NY: IBM Corps, USA).3 | Results
3.1 | Sociodemographic and clinical characteristics
The response rate of this study was 83% (n = 1643). There were no
differences in sociodemographic and clinical characteristics between
respondents, nonrespondents, and those with nonverifiable addresses
(data not shown). Of the 500 survivors who were given chemother-
apy, 471 had complete data on sensory CIPN.
Of these survivors, those with high CIPN (ie, upper 30% of scores,
mean sensory CIPN = 24.9) (n = 172) had significantly more comorbid
conditions, more often reported having osteoarthritis, were diagnosed
more recently, and were more often diagnosed with colon cancer
instead of rectal cancer compared with those with low CIPN (ie, the
other 70%, mean sensory CIPN = 2.8) (n = 299) (Table 1).3.2 | Comparing high versus low CIPN on
psychological distress and fatigue
CRC survivors with high CIPN reported more anxiety (M = 5.5, SD =
3.8 vs M = 4.1, SD = 3.5; P < 0.001) and depressive symptoms
(M = 5.1, SD = 4.0 vs M = 3.9, SD = 3.4; P = 0.001) compared with
those with low CIPN. However, these differences were not clinically
relevant. Using the cutoff score of 8, the prevalence of anxiety (30%
vs 19%; P = 0.007) and depression (27% vs 14%; P < 0.001) was higher
among survivors with high CIPN than those with low CIPN. Regarding
fatigue, those with high CIPN reported more fatigue (M = 23.1, SD =
7.3 vs M = 19.0, SD = 5.8; P < 0.001) than those with low CIPN. This
difference was clinically relevant.
TABLE 2 Simple mediation analyses of anxiety and depression as a mediator in the relationship between chemotherapy‐induced sensory
peripheral neuropathy symptoms and fatigue (N = 424)
Outcome Variable
Anxiety (M1) Fatigue
Ba SE P Ba SE P
CIPNb 1.28 0.38 <0.001 2.62 0.55 <0.001
Anxiety (M1) ‐ ‐ ‐ 0.92 0.72 <0.001
Constant 6.20 1.93 <0.001 22.36 2.84 0.001
Depression (M2) Fatigue
Ba SE P Ba SE P
CIPNb 0.95 0.37 0.01 2.72 0.49 <0.001
Depression (M2) ‐ ‐ ‐ 1.14 0.07 <0.001
Constant 5.43 1.90 0.005 21.89 2.54 <0.001
Notes. Confounding background variables included are age, sex, time since diagnosis, number of comorbid conditions, stage, partner status, educational
level, and tumor type (rectal vs colon).
Abbreviations: CIPN, chemotherapy‐induced sensory peripheral neuropathy; M, mediator.
aValues are unstandardized betas.
bHigh CIPN (ie, upper 30% of scores) versus low CIPN (ie, the other 70% of scores).
1930 BONHOF ET AL.3.3 | Anxiety and depression as mediators between
CIPN and fatigue
First, among those with high CIPN, fatigue scores were compared
according to their anxiety and depression level (Figure 1). Compared
with survivors with high CIPN only, those who were also anxious,
depressed, or both reported more fatigue. Moreover, survivors who
were both anxious and depressed reported more fatigue compared
with those with high CIPN who were only anxious or depressed. All
differences were clinically relevant.
Second, simple mediation analyses showed that a high CIPN
level was directly associated with more anxiety and fatigue (Table 2).
Moreover, anxiety was directly associated with fatigue as well. The
bootstrap results for the indirect effect of CIPN on fatigue revealed
that anxiety significantly mediated the effect of CIPN on fatigue
(B = 1.18, 95% CI 0.54‐1.96). For depression, results showed that a
high CIPN level was directly associated with more depressiveFIGURE 2 Multiple mediation analysis of anxiety and depressive
symptoms as mediators in the association between chemotherapy‐
induced sensory peripheral neuropathy and fatigue.Unstandardized
beta's are reported. *P < 0.05, **P < 0.01, ***P < 0.001symptoms and fatigue. In addition, depressive symptoms were directly
related to fatigue. Finally, depression was shown to significantly medi-
ate the effect of CIPN on fatigue (B = 1.08, 95% CI 0.22‐2.02).
In the multiple mediation model, in which the two possible media-
tors were simultaneously added to the model, both anxiety (B = 0.48,
95% CI 0.18‐1.01) and depression (B = 0.86, 95% CI 0.20‐1.69)
remained significant mediators in the relationship between CIPN and
fatigue (total effect = B = 1.34, 95% CI 0.47‐2.34) (Figure 2).4 | CONCLUSIONS
In this secondary analysis of a large population‐based study among
long‐term chemotherapy‐treated CRC survivors, we first demon-
strated that survivors with high CIPN reported more fatigue. In addi-
tion, those with high CIPN reported more anxiety and depression,
which in turn increased their fatigue levels even more. Finally, both
anxiety and depression were significant mediators in the relationship
between CIPN and fatigue.4.1 | Association between CIPN, psychological
distress, and fatigue
Our first aim was to examine whether CIPN was associated with both
psychological distress and fatigue. Regarding psychological distress,
survivors with a high CIPN level reported more anxiety and depressive
symptoms compared with those with a low CIPN level. The results are
in line with several prior studies, in which a positive association
between CIPN and either anxiety14-16 or depression14,15,17 was also
found.While we cannot determine causality due to the cross‐sectional
nature of our study, previous studies have indicated that the associa-
tion between CIPN and psychological distress may be bidirectional.
BONHOF ET AL. 1931On the one hand, CIPN symptoms could induce psychological distress
due to the pain associated with CIPN and the limitations in the
patient's ability to perform tasks independently.31 In addition, CIPN
might serve as a constant reminder of having (had) cancer, which could
also contribute to anxiety and depression. Reversely, people with a
high level of anxiety or depressive symptoms may actually be likely
to report more CIPN symptoms.16 One of the possible biological
mechanisms that have been suggested to play a role is an increased
production of proinflammatory cytokines, which has been related to
both anxiety and CIPN.32,33 Moreover, proinflammatory cytokines
that are produced in an anxious condition might interfere with recov-
ery from the nerve injury in CIPN. People with depressive symptoms
may also be likely to report more CIPN, as the deficits of serotonin
and norepinephrine in their brain might lead to the amplification of
minor signals from the body, causing an increased attention to bodily
symptoms.34 Also, given that antidepressants such as duloxetine have
been shown to be helpful in reducing CIPN6 supports evidence for a
biological link between psychological stress factors and CIPN. While
in the current student, differences in anxiety and depressive symp-
toms between survivors with high versus low CIPN were all statisti-
cally significant, none were clinically relevant. This could be due to
the particular sample of this study, as survivors were at least 2 years
after diagnosis. Survivors could have learned to accept or at least deal
with the CIPN symptoms over time. This could explain the rather small
differences in anxiety and depression scores between survivors with a
high and a low CIPN level. Future studies are needed that examine the
association between CIPN and psychological distress shortly after, or
even during chemotherapy.
Regarding the relationship between CIPN and fatigue, the results
are in line with previous studies.3,5,11 Among cancer patients, CIPN
has been associated with higher degrees of sleep disturbance, poor
sleep quality,14,15,17 and less physical activity,35 which could lead to
more fatigue. Elevated proinflammatory cytokines might play a role
here as well, as both CIPN and fatigue have been associated with ele-
vated proinflammatory cytokines.33,364.2 | Mediation of psychological distress in the
association between CIPN and fatigue
The second aim of our study was to examine whether the relationship
between CIPN and fatigue would be mediated by anxiety and depres-
sion. Both anxiety and depression were found to be associated with
fatigue and to mediate the relationship between CIPN and fatigue.
While prior studies did find anxiety and depression to be predictors
of fatigue,12,13 this is the first study that has examined anxiety and
depression as possible mediators in the association between CIPN
and fatigue. Both anxiety and depression may affect fatigue in various
ways. It could be that patients with CIPN who are depressed experi-
ence more fatigue, because they either lack the motivation to exer-
cise37 or because of the sleep disturbances often associated with
depression.38 Anxious patients with CIPN may be less physically active
because of the fall risk among those with neuropathy in the feet14 orbecause they may belief that too much activity could worsen CIPN
symptoms. Also, the high‐stress responses that those with anxiety
often experience may increase levels of fatigue. However, as existing
research has yet been able to determine the direction of the relation-
ship between psychological distress and fatigue, only tentative infer-
ences can be made.4.3 | Study limitations
This study has some limitations that need to be mentioned. First, we
only focused on sensory symptoms of CIPN, as a previous study in
the same sample of CRC survivors only found differences in these
symptoms between survivors who underwent chemotherapy and
those that did not.3 However, the CRC survivors were 2 to 12 years
after diagnosis. It is possible that CRC survivors do experience high
motor and autonomic neuropathy in the first year after diagnosis
and that these symptoms are associated with psychological distress
and fatigue. Also, nonrespondents could have declined to participate
due to CIPN symptoms in their hands or because of symptoms of
fatigue or psychological distress, which could have resulted in an
underestimation of the results of this study. In addition, data on the
chemotherapy regimen (eg, type of chemotherapy, number of cycles)
were not available, while this influences the severity of CIPN.2 Also,
besides diabetes mellitus, rheumatoid arthritis, and osteoarthritis, we
do not have information on other conditions that could have affected
the neuropathy symptoms. Furthermore, while using a self‐reported
questionnaire to assess CIPN is necessary due to the subjective nature
of the symptoms, the lack of a clinical diagnosis of CIPN is another lim-
itation of this study. Finally, the cross‐sectional nature of this study
limits the determination of causal associations. For example, it could
be that the association between psychological distress and fatigue is
in fact mediated by CIPN.
Despite these limitations, this is the first study that has examined
anxiety and depression as possible mediators in the relationship
between CIPN and fatigue. Also, we feel that this study provides valu-
able new insights into the limited available data on the relationship
between CIPN and anxiety, depression, and fatigue. In addition, we
used the FAS to measure fatigue, which takes more elements of
fatigue into account compared with the EORTC QLQ‐C30 fatigue sub-
scale, which was mostly used in prior studies. Further, as this was a
large population‐based study with a high response rate, we feel that
our findings can be generalized to the general CRC survivors' popula-
tion treated with chemotherapy.4.4 | Clinical implications
Given that this was a cross‐sectional study, no clear statements can be
made regarding the causality in the relationship between CIPN, psy-
chological distress, and fatigue. Further studies are needed that focus
on the interrelationship between CIPN, psychological distress, and
fatigue. For example, intervention studies aimed at improving
1932 BONHOF ET AL.psychological distress could be evaluated on its concomitant effect on
CIPN and fatigue.
For clinical practice, this study first shows that interventions for
CRC survivors with high CIPN are needed, as they report clinically rel-
evant higher fatigue levels. Further, CRC patients with CIPN who
report fatigue should be screened for psychological distress, as those
with anxiety and/or depression report the most fatigue. Accordingly,
in the treatment of fatigue, treatment should also focus on the pres-
ence of anxiety and depression, as treating fatigue alone might not
be sufficient. Exercise and psychological interventions are recom-
mended, as these interventions have been proven to be effective
in reducing not only psychological distress and fatigue, but CIPN
as well.39,40
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